Wang Xiaohua, Yin Xiaoguang, Sun Wei, Bai Jin, Shen Yawen, Ao Qiang, Gu Yongquan, Liu Ying
Department of Hematology, Siping Hospital of China Medical University, Siping, Jilin 136000, P.R. China.
Jilin Tuhua Bioengineering Company Ltd., Siping, Jilin 136000, P.R. China.
Exp Ther Med. 2017 May;13(5):2255-2258. doi: 10.3892/etm.2017.4229. Epub 2017 Mar 14.
Four patients with chronic refractory immune thrombocytopenic purpura (ITP) received human umbilical cord-derived mesenchymal stem cells (hUC-MSCs). The hUC-MSC dose was 5×10 to 1×10. Complete remission (CR) was achieved in three patients in 12 months and one patient in 24 months. Three patients received the second hUC-MSC transplantation with the same dose. The median time between hUC-MSC transplantation and response was 12.5 days (range, 7-16). There were no severe adverse events during and post hUC-MSC transplantation. During follow-up (median, 17 months; range, 13-24) no other immunosuppressive drugs were used post-first hUC-MSCs transplantation. In conclusion, hUC-MSC transplantation is a reasonable salvage treatment in chronic refractory ITP. Prospective randomized large-scale clinical trials are needed to further elucidate the efficacy of hUC-MSCs transplantation therapy on ITP.
4例慢性难治性免疫性血小板减少性紫癜（ITP）患者接受了人脐带间充质干细胞（hUC-MSCs）治疗。hUC-MSCs的剂量为5×10至1×10。3例患者在12个月内实现完全缓解（CR），1例患者在24个月内实现完全缓解。3例患者接受了相同剂量的第二次hUC-MSCs移植。hUC-MSCs移植与缓解之间的中位时间为12.5天（范围7-16天）。hUC-MSCs移植期间及移植后均未发生严重不良事件。在随访期间（中位时间17个月；范围13-24个月），首次hUC-MSCs移植后未使用其他免疫抑制药物。总之，hUC-MSCs移植是慢性难治性ITP的一种合理挽救治疗方法。需要进行前瞻性随机大规模临床试验，以进一步阐明hUC-MSCs移植治疗ITP的疗效。
